NCT01530373 – A Phase II Randomized Study of Solifenacin Compared to Clonidine for Reducing Hot Flashes among Breast Cancer Patients Receiving Adjuvant Hormonal Therapy

Hot flashes present a considerable problem for many breast cancer patients; these symptoms may be intensified by hormonal therapies, such as aromatase inhibitors or tamoxifen. This study examines the value of solifenacin (a muscarinic acetylcholine receptor antagonist) in reducing hot flashes, compared with clonidine (a medication often used for treating hot flashes).

Learn More